Price (delayed)
$18.87
Market cap
$550.24M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.64
Enterprise value
$480.49M
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically
There are no recent dividends present for BTAI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.